Orion Corporation

Arja Karjalainen

Gerd Wohlfahrt

Olli Törmäkangas

Harri Salo

Anniina Vesalainen

Paavo Huhtala

Patrik Holm

Sirpa Rasku

Iisa Höglund

Arto J Karjalainen

Pia Koivikko

Jari Ratilainen

Raimo E Virtanen

Maire Eloranta

Juha-Matti Savola

Antti Haapalinna

Siegfried Wurster

Jyrki Lehtim&auml;ki

Victor Cockcroft

Anu Moilanen

Maarit Hillil&auml;

Raimo Saxlund

Eija Tiainen

Anssi Haikarainen

Petteri Rummakko

Pekka Pietikäinen

Terhi Heikkinen

Mikko Passiniemi

Emilia Väisänen

Pranab Kumar Patra

Pia Knuuttila

Rathna Durga Ramasubramanian

Arputharaj Ebenezer Martin

Pekka Kallio

Olli Toermaekangas

Iisa Hoeglund

Olli Tormakangas

Lisa HÖGLUND

The present disclosure relates to compounds of formula (I), and pharmaceutically acceptable salts thereof. The present disclosure also relates to compositions and methods of treating comprising compounds of formula (I), and pharmaceutically acceptable salts thereof. 

Androgen receptor modulating compounds

CYP17 inhibitors/antiandrogens

The present disclosure relates to compounds of formula (I), and pharmaceutically acceptable salts thereof. The present disclosure also relates to compositions and methods of treating comprising compounds of formula (I), and pharmaceutically acceptable salts thereof.

Compounds of formula (I) or (II) wherein R, R, R, R, R, R', R, R&#x2032;, A and B are as defined in the claims and pharmaceutically acceptable salts and esters thereof, are disclosed. The compounds possess utility as tissue-selective androgen receptor modulators (SARM) and are useful as medicaments in the treatment of prostate cancer and other AR dependent conditions and diseases where AR antagonism is desired.

Androgen receptor modulating carboxamides

A compound of formula (I), an isomer, metabolite, or a pharmaceutically acceptable salt or ester thereof is disclosed. Compounds of the invention possess utility as a tissue-selective androgen receptor modulators (SARM) and are useful in hormonal therapy, e.g. in the treatment or prevention of hypogonadism, muscle wasting, osteoporosis, benign prostate hyperplasia, obesity associated with a metabolic syndrome, male and female sexual dysfunction and reduced libido, and androgen decline in aging male or female.

Selective androgen receptor modulators

Compounds of formula (I) wherein R1 to R4, X and A are as defined in the claims and pharmaceutically acceptable salts and esters thereof, are disclosed. The compounds of formula (I) possess utility as tissue-selective androgen receptor modulators (SARM) and are useful in hormonal therapy, e.g., in the treatment or prevention of male hypogonadism and age-related conditions such as andropause.

Growing community of inventors

Espoo, Finland

Arja Karjalainen